Wednesday, February 18, 2026 2/18/2026

A Personalized Gene Therapy Approach for Charcot-Marie-Tooth Disease

Award Number: F31NS098540
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 03/02/2017
PERIOD OF PERFORMANCE END DATE: 05/12/2018

Group Awards By:

View Award Description

A Personalized Gene Therapy Approach for Charcot-Marie-Tooth Disease - PROJECT SUMMARY Charcot-Marie-Tooth Disease (CMT) is a heterogeneous collection of inherited polyneuropathies generallyCharacterize dby progressive muscle weakness and loss of sensation in the extremities. This disorder, for which there is currently no curative treatment, is the most common inherited disorder of the peripheral nervous system, affecting 1:2,500 individuals. Over 80 loci in the human genome have been linked to CMT, indicating that diverse cellular pathways are involved in its etiology. Fortunately, some common pathological mechanisms arebeginning to emerge, as thirteen different autosomal dominant mutations in GARS (glycyl-tRNA synthetase) have been identified in patients with CMT Type 2D (CMT2D). Although the mechanisms through which mutant forms of GARS cause axon degeneration are unclear, data from humans, mice, and Drosophila are consistent with the expression of mutant GARS protein causing toxic gain-of-function effects in peripheral nerves. Thus, our central hypothesis is that the selective silencing of mutant GARS expression should be of therapeutic benefit for patients with CMT2D. In response, we have developed a gene therapy strategy that specifically reduces mutant Gars expression through allele-specific RNAi. Recent exciting preliminary data confirms that when administered at birth, RNAi targeting mutant-Gars significantly improves all neuropathy outcome measures in an established mouse model of CMT2D (GarsP278KY/+). The overall objective for this proposal is to complete three specific aims designed to use mutant-Gars targeting RNAi as a powerful tool to gain novel mechanistic insights underlying CMT2D and to optimize the therapeutic potential of our gene therapy strategy. In Aim 1 we will assess the efficacy of Gars-targeting RNAi in the prevention of neuropathy when delivered directly into the nervous system compared to its systemic delivery in GarsP278KY/+ mice. This study will determine if the disease is primarily driven by a cell autonomous or non- autonomous mechanism and establish the optimal route of delivery for our gene therapy approach. In Aim 2 we will assess the potential for mutant Gars-targeting RNAi to arrest neuropathy in adult GarsP278KY/+ mice. This study will help us understand how neuropathy begins and progresses, and will help determine if our gene therapy strategy can treat current patients with CMT2D. The objective of Aim 3 is to generate “humanized” preclinical mouse models that have a CMT2D patient-associated mutation substituted into the mouse Gars gene. This work will provide an in vivo platform to test personalized therapeutic strategies on disease-relevant mutations in in vivo models with established phenotypic validity. This study is significant and innovative, as we will demonstrate critical preclinical proof-of-concept data to help accomplish our long-term goal of developing a gene therapy for patients with CMT2D. This will be the first effective treatment for CMT2D or any dominant form of CMT and will have broad translational impact as it has implications for other common neuromuscular disorders including Huntington’s disease and motor neuron disorders.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = -$17,155 )
2021	2018	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	1/12/2021	NON-COMPETING CONTINUATION	-$15,217
2021	2018	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	12/29/2020	NON-COMPETING CONTINUATION	-$1,938
														Subtotal = -$17,155

Issue Date FY: 2019 ( Subtotal = -$19,513 )
2019	2018	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	6/21/2019	NON-COMPETING CONTINUATION	-$19,513
														Subtotal = -$19,513

Issue Date FY: 2018 ( Subtotal = $34,730 )
2018	2018	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	5/15/2018	NON-COMPETING CONTINUATION	$480
2018	2018	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	2/16/2018	NON-COMPETING CONTINUATION	$34,250
														Subtotal = $34,730

Issue Date FY: 2017 ( Subtotal = $34,250 )
2017	2017	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	3/2/2017	NEW	$33,782
2017	2017	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	1	7/7/2017	NEW	$468
2017	2017	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	1	3/2/2017	NEW	$0
														Subtotal = $34,250

Grand Total All Awards = $32,312

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Personalized Gene Therapy Approach for Charcot-Marie-Tooth Disease

Award Number: F31NS098540

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 03/02/2017

PERIOD OF PERFORMANCE END DATE: 05/12/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer